M/s Panacea Biotech, New Delhi
Recipient of “BioSpectrum Product of the year Award, 2011”
And “India Nanotech Innovation Award, 2011”.
M/s Panacea Biotec is the first Indian company to have indigenously developed and commercialized an innovative product “PacliALL”, a nano-technology based formulation of albumin-bound Paclitaxel particles for effective treatment of breast cancer. PacliALL uses one of the world’s most advanced particle size optimization technology to reduce serious adverse effects, including severe anaphylaxis and sensory neuropathy associated with conventional Paclitaxel formulations.
The Company has offered PacliALL at 50% lower cost to patients in India. The Company has set up a manufacturing facility at Baddi with an annual capacity of 1.2 million vials, investing Rs.55 Crores out of which TDB has provided Rs.5 Cr.as term loan at a concessional rate of interest.
Panacea Biotec is an Innovation driven Biotechnology company doing Research and Development, Manufacturing, Sales, Distribution and Marketing of Pharmaceuticals and Vaccines. Panacea Biotec was set up in the year 1984, under the name of Panacea Drugs Private Limited with a commitment to make Innovative Products Affordable and Accessible to the masses. It got publically listed on Indian National Stock Exchanges in September 1995 as Panacea Biotec Ltd. Our aspirations are supported by our Globally accredited USFDA approved pharmaceutical manufacturing facility at Baddi, WHO pre-qualified facilities for vaccine production at Lalru (Punjab) and Baddi. The international pharmaceutical formulations product portfolio includes highly innovative prescription products in niche therapeutic areas such as Pain, Diabetes & Cardiovascular management, Oncology, Renal Disease, Osteoporosis management and Gastro-intestinal care. Our first Nanotechnology based product ‘PacliAll’ (Paclitaxel in protein bound particles) was launched in 2011; it was the world’s first generic for Abraxane, manufactured by Celegene USA. Panacea Biotec has consolidated its presence in about 30 markets across CIS, Latin America, Middle East, Asia & Africa
Published on : 10th October, 2023